Solid Tumor Panel
The Sema4 Solid Tumor Panel uses next-generation sequencing (NGS) technology to detect actionable mutations in solid tumor cancers, including lung cancer, colorectal cancer, skin cancer (melanoma), breast cancer, brain cancer, and thyroid cancer. It delivers highly accurate insight into the genomic profiles of solid tumors. The Solid Tumor Panel is >99% sensitive and specific when compared against a series of cases with known or previously-tested mutations by other NGS methods.
The Solid Tumor Panel analyzes 161 of the most relevant cancer driver genes for clinically significant mutations, including
- Single nucleotide variants (SNVs), insertions and deletions (indels), gene fusions, copy number alterations (CNAs), and certain splice variants using DNA and RNA
- National Comprehensive Cancer Network (NCCN) and other guideline-recommended markers
- Gene targets that are relevant for clinical trial selection
The Solid Tumor Panel is part of a comprehensive care plan designed to help clinicians optimize treatment selection and planning, identify relevant clinical trials, and provide prognostic information, where available. It tests for 99% of guideline-recommended genes, 117 genes included in 800+ clinical trials worldwide, and 9 genes associated with 36 targeted therapies approved by the FDA. To view a full list of the genes that this test screens for, please download the clinical brochure.
- Preferred 10 unstained slides at 10 μm thickness and one matching H&E stained slide. Minimum 5 unstained slides and one matching H&E stained slide
- Preferred >10 mm2 and ≥50% tumor content. Minimum 10% tumor content
- Slides must be labeled with two unique identifiers. Slides should also be properly labeled with a block label identity that corresponds with the surgical pathology report
- FFPE blocks may be accepted with prior approval from Sema4
- Please include a surgical pathology report with the specimen submission
- 10-14 days from receipt of specimen
Solid Tumor Panel Clinical Brochure